ORGO vs SN.L
ORGO: Organogenesis is a tissue-engineered wound care and surgical reconstruction company whose financial health depends critically on Medicare reimbursement rates and FDA regulatory compliance. SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions.
Side-by-side fundamentals
| Metric | ORGO | SN.L | Edge |
|---|---|---|---|
| Price as of 2026-08-21 close | $1.80 | £10.74 | |
| Market cap as of 2026-08-24 | $232M | n/a | |
| P/E as of 2026-08-24 | 84.95 | n/a | |
| PEG as of 2026-08-24 | -0.00 | n/a | |
| Net margin as of 2026-08-24 | +0.5% | n/a | |
| Gross margin as of 2026-08-24 | +72.9% | n/a | |
| Operating margin as of 2026-08-24 | +0.5% | n/a | |
| ROE as of 2026-08-24 | +0.7% | n/a | |
| ROA as of 2026-08-24 | +0.5% | n/a | |
| Debt / equity as of 2026-08-24 | 0.03 | n/a | |
| Revenue growth (YoY) as of 2026-08-24 | +12.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | +7.8% | n/a | |
| Beta as of 2026-08-24 | 1.28 | n/a | |
| 1-year return as of 2026-08-21 close | -59.7% | -22.8% | SN.L higher |
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.